Annual EBIT
-$58.47 M
-$35.31 M-152.41%
31 December 2023
Summary:
BioLineRx annual earnings before interest & taxes is currently -$58.47 million, with the most recent change of -$35.31 million (-152.41%) on 31 December 2023. During the last 3 years, it has fallen by -$29.92 million (-104.79%). BLRX annual EBIT is now -1678.93% below its all-time high of $4.21 million.BLRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$4.20 M
-$6.77 M-263.37%
30 September 2024
Summary:
BioLineRx quarterly earnings before interest & taxes is currently -$4.20 million, with the most recent change of -$6.77 million (-263.37%) on 30 September 2024. Over the past year, it has increased by +$10.99 million (+72.36%). BLRX quarterly EBIT is now -119.99% below its all-time high of $20.99 million, reached on 30 September 2010.BLRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$16.24 M
+$10.99 M+40.36%
30 September 2024
Summary:
BioLineRx TTM earnings before interest & taxes is currently -$16.24 million, with the most recent change of +$10.99 million (+40.36%) on 30 September 2024. Over the past year, it has increased by +$32.17 million (+66.46%). BLRX TTM EBIT is now -276.86% below its all-time high of $9.18 million, reached on 30 June 2011.BLRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BLRX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -152.4% | +72.4% | +66.5% |
| 3 y3 years | -104.8% | +23.1% | +51.6% |
| 5 y5 years | -157.9% | -25.6% | +17.2% |
BLRX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -152.4% | at low | -263.4% | +75.6% | at high | +72.2% |
| 5 y | 5 years | -157.9% | at low | -263.4% | +75.6% | at high | +72.2% |
| alltime | all time | -1678.9% | at low | -120.0% | +75.6% | -276.9% | +72.2% |
BioLineRx EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.20 M(-263.4%) | -$16.24 M(-40.4%) |
| June 2024 | - | $2.57 M(+1002.6%) | -$27.23 M(-42.1%) |
| Mar 2024 | - | $233.00 K(-101.6%) | -$47.00 M(-19.6%) |
| Dec 2023 | -$58.47 M(+152.4%) | -$14.84 M(-2.3%) | -$58.47 M(+20.8%) |
| Sept 2023 | - | -$15.19 M(-11.8%) | -$48.41 M(+21.6%) |
| June 2023 | - | -$17.21 M(+53.2%) | -$39.80 M(+34.2%) |
| Mar 2023 | - | -$11.23 M(+135.2%) | -$29.66 M(+28.0%) |
| Dec 2022 | -$23.16 M(-11.1%) | -$4.78 M(-27.4%) | -$23.16 M(+2.9%) |
| Sept 2022 | - | -$6.58 M(-6.9%) | -$22.51 M(+5.3%) |
| June 2022 | - | -$7.06 M(+48.9%) | -$21.39 M(+2.2%) |
| Mar 2022 | - | -$4.74 M(+15.1%) | -$20.92 M(-19.8%) |
| Dec 2021 | -$26.07 M(-8.7%) | -$4.12 M(-24.4%) | -$26.07 M(-22.4%) |
| Sept 2021 | - | -$5.46 M(-17.3%) | -$33.58 M(+3.5%) |
| June 2021 | - | -$6.60 M(-33.3%) | -$32.44 M(+0.7%) |
| Mar 2021 | - | -$9.89 M(-14.9%) | -$32.21 M(+12.8%) |
| Dec 2020 | -$28.55 M(+23.1%) | -$11.63 M(+169.5%) | -$28.55 M(+9.7%) |
| Sept 2020 | - | -$4.32 M(-32.3%) | -$26.02 M(+3.9%) |
| June 2020 | - | -$6.37 M(+2.3%) | -$25.05 M(+5.6%) |
| Mar 2020 | - | -$6.23 M(-31.5%) | -$23.72 M(+2.3%) |
| Dec 2019 | -$23.19 M(+2.3%) | -$9.10 M(+172.3%) | -$23.19 M(+18.3%) |
| Sept 2019 | - | -$3.34 M(-33.8%) | -$19.60 M(-13.2%) |
| June 2019 | - | -$5.04 M(-11.6%) | -$22.57 M(+1.2%) |
| Mar 2019 | - | -$5.71 M(+3.6%) | -$22.31 M(-1.3%) |
| Dec 2018 | -$22.67 M(-6.9%) | -$5.51 M(-12.8%) | -$22.59 M(-7.6%) |
| Sept 2018 | - | -$6.31 M(+32.2%) | -$24.45 M(-3.6%) |
| June 2018 | - | -$4.78 M(-20.3%) | -$25.38 M(-0.5%) |
| Mar 2018 | - | -$5.99 M(-18.7%) | -$25.50 M(+4.7%) |
| Dec 2017 | -$24.35 M | -$7.37 M(+1.9%) | -$24.35 M(+10.9%) |
| Sept 2017 | - | -$7.24 M(+47.9%) | -$21.95 M(+15.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$4.89 M(+0.9%) | -$19.04 M(+6.5%) |
| Mar 2017 | - | -$4.85 M(-2.4%) | -$17.88 M(+8.3%) |
| Dec 2016 | -$16.51 M(+2.0%) | -$4.97 M(+14.8%) | -$16.51 M(-3.4%) |
| Sept 2016 | - | -$4.33 M(+16.1%) | -$17.10 M(+19.5%) |
| June 2016 | - | -$3.73 M(+7.0%) | -$14.31 M(-7.0%) |
| Mar 2016 | - | -$3.48 M(-37.3%) | -$15.39 M(-5.0%) |
| Dec 2015 | -$16.20 M(-6.1%) | -$5.56 M(+262.1%) | -$16.20 M(-24.3%) |
| Sept 2015 | - | -$1.53 M(-68.1%) | -$21.40 M(+4.1%) |
| June 2015 | - | -$4.81 M(+12.0%) | -$20.56 M(+6.1%) |
| Mar 2015 | - | -$4.29 M(-60.1%) | -$19.39 M(+13.2%) |
| Dec 2014 | -$17.25 M(+1.5%) | -$10.76 M(+1437.0%) | -$17.13 M(+42.0%) |
| Sept 2014 | - | -$700.00 K(-80.7%) | -$12.06 M(-23.5%) |
| June 2014 | - | -$3.63 M(+78.6%) | -$15.76 M(-1.0%) |
| Mar 2014 | - | -$2.03 M(-64.3%) | -$15.93 M(-5.5%) |
| Dec 2013 | -$17.01 M(-22.1%) | -$5.69 M(+29.3%) | -$16.85 M(-19.2%) |
| Sept 2013 | - | -$4.40 M(+15.9%) | -$20.86 M(-4.2%) |
| June 2013 | - | -$3.80 M(+28.4%) | -$21.77 M(+4.6%) |
| Mar 2013 | - | -$2.96 M(-69.5%) | -$20.82 M(-5.7%) |
| Dec 2012 | -$21.83 M(+41.7%) | -$9.70 M(+82.4%) | -$22.09 M(+13.5%) |
| Sept 2012 | - | -$5.32 M(+86.8%) | -$19.46 M(+19.7%) |
| June 2012 | - | -$2.85 M(-32.6%) | -$16.26 M(-8.7%) |
| Mar 2012 | - | -$4.23 M(-40.2%) | -$17.81 M(+10.5%) |
| Dec 2011 | -$15.41 M(-516.1%) | -$7.07 M(+234.3%) | -$16.12 M(+15.7%) |
| Sept 2011 | - | -$2.12 M(-52.0%) | -$13.93 M(-251.7%) |
| June 2011 | - | -$4.40 M(+73.7%) | $9.18 M(+62.6%) |
| Mar 2011 | - | -$2.53 M(-48.0%) | $5.64 M(+33.2%) |
| Dec 2010 | $3.70 M | -$4.88 M(-123.2%) | $4.24 M(-53.5%) |
| Sept 2010 | - | $20.99 M(-364.5%) | $9.11 M(-176.7%) |
| June 2010 | - | -$7.94 M(+101.4%) | -$11.88 M(+201.4%) |
| Mar 2010 | - | -$3.94 M | -$3.94 M |
FAQ
- What is BioLineRx annual earnings before interest & taxes?
- What is the all time high annual EBIT for BioLineRx?
- What is BioLineRx annual EBIT year-on-year change?
- What is BioLineRx quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BioLineRx?
- What is BioLineRx quarterly EBIT year-on-year change?
- What is BioLineRx TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BioLineRx?
- What is BioLineRx TTM EBIT year-on-year change?
What is BioLineRx annual earnings before interest & taxes?
The current annual EBIT of BLRX is -$58.47 M
What is the all time high annual EBIT for BioLineRx?
BioLineRx all-time high annual earnings before interest & taxes is $4.21 M
What is BioLineRx annual EBIT year-on-year change?
Over the past year, BLRX annual earnings before interest & taxes has changed by -$35.31 M (-152.41%)
What is BioLineRx quarterly earnings before interest & taxes?
The current quarterly EBIT of BLRX is -$4.20 M
What is the all time high quarterly EBIT for BioLineRx?
BioLineRx all-time high quarterly earnings before interest & taxes is $20.99 M
What is BioLineRx quarterly EBIT year-on-year change?
Over the past year, BLRX quarterly earnings before interest & taxes has changed by +$10.99 M (+72.36%)
What is BioLineRx TTM earnings before interest & taxes?
The current TTM EBIT of BLRX is -$16.24 M
What is the all time high TTM EBIT for BioLineRx?
BioLineRx all-time high TTM earnings before interest & taxes is $9.18 M
What is BioLineRx TTM EBIT year-on-year change?
Over the past year, BLRX TTM earnings before interest & taxes has changed by +$32.17 M (+66.46%)